pharmaceutical giant Cipla has introduced a three-in-one aids drug called Triomune. The new drug is a combination of stavudine, lamivudine and nevirapine. Cipla could synthesise the drug because Indian laws allow generic copies to be made. The generic drug would remain one of its kind, as the patent holders of the three drugs are unlikely to form an alliance for a similar offer. Triomune has several advantages over the three drugs. With its introduction, the treatment cost has been slashed from Rs 2,000 to Rs 1,800. Along with this, the dosage has also been reduced
Technology Partners: MimirTech
Links:
[1] http://admin.indiaenvironmentportal.org.in/news/three-one-offer
[2] http://admin.indiaenvironmentportal.org.in/category/newspaper/down-earth
[3] http://admin.indiaenvironmentportal.org.in/category/thesaurus/trade
[4] http://admin.indiaenvironmentportal.org.in/category/thesaurus/health
[5] http://admin.indiaenvironmentportal.org.in/category/thesaurus/medical-research
[6] http://admin.indiaenvironmentportal.org.in/category/thesaurus/drugs
[7] http://admin.indiaenvironmentportal.org.in/category/thesaurus/drug-industry
[8] http://admin.indiaenvironmentportal.org.in/category/thesaurus/aids
[9] http://admin.indiaenvironmentportal.org.in/category/thesaurus/india
[10] http://admin.indiaenvironmentportal.org.in/category/thesaurus/developing-countries
